Boehringer Ingelheim Kg

Celamerck Gmbh & Co. Kg

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim International Gmbh

Shell Internationale Research Maatschappij, B.v.

Celamerck, Gesellschaft MIT Beschrankter Haftung & Co. Kg

Werner Stransky

Helmut Ensinger

Karl-Heinz Weber

Gerhard Walther

Franz J Kuhn

Wolf-Dietrich Bechtel

Ludwig Schroder

Rudolf Mengel

Gerbert Linden

Ulrike Kufner-Muhl

Erich Lehr

Gunter Schingnitz

Sigmund Lust

Hubert Heuer

Karl H Weber

Enzio Muller

Albrecht Harreus

Matthias Grauert

Gojko Muacevic

Franz Birke

Adrian Carter

Gerhart Schneider

Herbert Merz

Klaus Fuchs

Thomas Weiser

Ilse Streller

Jorge C Stenzel

Enzio Mueller

Stefan Peters

Herbert Nar

Christian Eickmeier

Jorge Casals-Stenzel

Sandra Handschuh

Cornelia Dorner-Ciossek

Wolfram Gaida

Klaus Klinder

Rainer Palluk

Marcus Kostka

Ulrike Kuefner-Muehl

Uwe Pschorn

Gerhard Waither

Gerhard Walther, Deceased

Ralf Richard H Lotz

Erich Raddatz

The invention relates to a compound of the formula (I) wherein R, R, R, R, R, R, Rand Rare defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.

Statine derivatives for the treatment of Alzheimer's disease III

Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines

The present patent application relates to new substituted 3-phenoxy- or 3-phenylalkyloxy-2-phenyl-propylamines of general formula 1, processes for preparing them and their use as pharmaceutical compositions.

Substituted 3-phenoxy- and 3-phenylalkyloxy-2-phenyl-propylamines

A hetrazepine of the formula given below and a pharmaceutical composition comprising a therapeutically effective amount of the hetrazepine and a pharmaceutically acceptable inert carrier are disclosed and are useful in treating disease in a warm-blooded animal induced by endogenously formed PAF; ##STR1## wherein the substituents are defined herein.

Acylamino-substituted hetrazepines

Novel benzomorphan derivatives of the formula ##STR1## wherein R.sup.1 -R.sup.8 are as defined herein. The benzomorphan derivatives are useful for treating cerebral ischaemia of various origins, epilepsy and neurodegenerative diseases.

Benzomorphan derivatives

The present invention relates to thienodiazepines of formula Ib: ##STR1## wherein U, V, R.sub.5, R.sub.6 and R.sub.7 are as defined herein. This invention also relates to processes for preparing these thienodiazepines and their use in pharmaceutical compositions with PAF-antagonistic activity.

Hetrazepinoid amides

The invention relates to new xanthine derivatives of general formula I, processes for preparing them and their use as pharmaceutical compositions.

Xanthine derivatives with adenosine-antagonistic activity

Bornyl xanthine derivatives with adenosine-antagonistic activity

New xanthine compounds of formula I: ##STR1## wherein the substituents are defined herein, which xanthines are useful as adenosine antagonists.

8-substituted 1,3-dialiphaticxanthine derivatives

Useful for treating neurodegenerative diseases

The invention relates to new hetrazepines of general formula ##STR1## wherein A, Z, n, X, Y, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the meanings given in the specification.

Hetrazepine compounds which have useful pharmaceutical utility

Xanthines of the formula I ##STR1## wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group:

The invention relates to new quinuclidines, processes for their preparation and their use as medicaments having cholinomimetic properties.

Quinuclidines, their use as medicaments and processes for their

The invention relates to quinuclidines, processes for their preparation and their use as medicaments having cholinomimetic properties.

The invention relates to new tetrahydropyridine derivatives, processes for preparing them and their use as pharmaceutical compositions with cholinomimetic properties.

Tetrahydropyridine derivatives

Growing community of inventors

Gau-Algesheim, Germany

Werner Stransky